ALX Oncology Holdings Inc.
HealthcareNASDAQ:ALXO · NASDAQ Global Select
+$0.06 today
Vol 0.64M · Avg 1.01M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-391.4%
avg 768.3%
ROIC
-262.0%
avg -126.9%
ROA
-172.2%
avg -88.2%
Analysis
ROA is currently the strongest return metric at -172.2% versus its period average of -88.2%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Jason W. Lettmann | Chief Executive Officer & Director | $1.02M | — | 49 | $293,609.00 | 0.22% |
Harish Shantharam | Chief Financial Officer | $642,867.00 | — | 45 | $303,000.00 | 0.23% |
Shelly Wong | Senior Vice President of Finance & Chief Accounting Officer | $578,466.00 | — | 49 | $86,805.00 | 0.06% |
Shelly Pinto | Senior Vice President of Finance & Chief Accounting Officer | $578,466.00 | — | 49 | $86,805.00 | 0.06% |
Barbara J. Klencke | Chief Medical Officer | $262,580.00 | — | 69 | $100,000.00 | 0.07% |
Lin Yeong-Liang | Senior Vice President of Drug Safety & Pharmacovigilance | — | — | — | — | — |
Lisa Sauer | Senior Vice President of Regulatory Affairs & Quality Assurance | — | — | — | — | — |
Venita De Almeida | Vice President & Head of Research Program Development | — | — | — | — | — |
Athanasios Tsiatis | Senior Vice President of Clinical Development | — | — | — | — | — |
Sue Naim | Senior Vice President of Clinical Operations | — | — | — | — | — |
Jeff E. Knight | Chief Development & Operating Officer | — | — | 54 | $800,000.00 | 0.59% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
4
$5.16M
Sells
8
$37,794.31
Net Sentiment
+$5.12M
Net buying
Most Active
Pinto Shelly
6 transactions
1–10 of 12
Analysis
Insiders reported 4 buys worth $5.16M and 8 sells worth $37,794.31 over the last 12 months. That adds up to net buying of $5.12M. Pinto Shelly was the most active insider with 6 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Sutro Biopharma, Inc.
NASDAQ:STRO
$278.70M
Artiva Biotherapeutics, Inc.
NASDAQ:ARTV
$211.08M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
Metagenomi, Inc. Common Stock
MGX
$45.18M
aTyr Pharma, Inc.
ATYR
$43.18M
Who manages ALXO?
ALX Oncology Holdings Inc. (ALXO) lists 11 active executives. The top listed executive is Harish Shantharam, Chief Financial Officer.
Are ALXO insiders buying or selling?
Recent insider activity shows net buying of $23.91M.
Explore More
Continue the stock analysis
Jump to another research area for this company.